Poloxamer 407 是一种非离子型表面活性剂，Poloxamer 407 具有 100% 的活性并且对细胞相对无毒性的，常与染料 AM 酯一起使用，以增强其水溶性。Poloxamer 407 也是一种lipoprotein lipase抑制剂。
| 生物活性 | Poloxamer 407 is a nonionic surfactant that is 100% active and relatively non-toxic to cells at low concentrations, and frequently used with dye AM esters such as Indo-1 AM, Fura-2 AM, Calcein AM, Fluo-3 AM, Fluo-4 AM, Quest Fluo-8(TM) AM and Quest Rhod-4(TM) AM, etc. to improve their water solubility. Poloxamer 407 is also alipoprotein lipaseinhibitor[1][2]. |
体外研究
(In Vitro) | Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs).
1. Dissolve 1 g of Poloxamer 407 in 10 mL distilled water to make a 10% (w/v) stock solution, or 2 g of Poloxamer 407 in 10 mL DMSO to make a 20% (w/v) stock solution. These may require heating from 40 to 50℃ for about 30 minutes. Store solution at room temperature. Do not refrigerate or freeze the Poloxamer 407 solution since it may precipitate. If precipitation is observed, the precipitates can be dissolved by heating to 37℃ and vortexing before use.
2. Dilute the 10% or 20% Poloxamer 407 stock solution into the cell-loading buffer such as Hanks and 20 mM Hepes buffer (HHBS) at 1:1000 to 1:500 dilution to achieve a 0.02 to 0.04% working solution.
3. The DMSO stock solution of AM ester is then diluted into the 0.02 to 0.04% working solution to achieve a final AM ester concentration between 1 μM and 10 μM. The final concentration of Poloxamer 407 is normally kept at or below 0.08%.
4. The cells are incubated at a desired temperature for between 10 minutes and 1 hour. In general it is desirable to use the minimum amount of AM ester needed to achieve adequate fluorescence signal to noise levels.
5. After labeling, the cells are washed with HHBS or fresh medium before starting the experiment.
|
体内研究
(In Vivo) | Poloxamer 407 (0.25 g/kg; i.p.; every other day for 7 weeks) induces hypertriglyceridemia but decreases atherosclerosis in Ldlr–/–mice[2].
| Animal Model: | Ldlr–/–mice[2] | | Dosage: | 0.25 g/kg | | Administration: | Intraperitoneal injection, every other day for 7 weeks | | Result: | Mice tended to have a lower body weight and had smaller epididymal fat pads compared to the saline controls, and had reduced atherosclerosis. |
|
| 分子量 | |
| 性状 | |
| CAS 号 | |
| 中文名称 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: H2O : 110 mg/mL(Need ultrasonic) In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： PBS Solubility: 50 mg/mL (Infinity mM); Clear solution; Need ultrasonic
*以上所有助溶剂都可在本网站选购。 |
m.cnreagent.com